Fig. 4: Exploratory analysis of a RNA-based TME assay. | Nature Communications

Fig. 4: Exploratory analysis of a RNA-based TME assay.

From: The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial

Fig. 4: Exploratory analysis of a RNA-based TME assay.The alternative text for this image may have been generated using AI.

a Tumors were classified into as immune-low or immune-high based on the Xerna TME Panel. Stacked bar graph depicts ORR of each patient subset (two-sided Fisher’s exact test p = 0.0408). ORR objective response rate, PR partial response, CR complete response, SD stable disease, PD progressive disease. b Kaplan-Meier curve shows the probability of progression-free survival over time among evaluable patients differentiated by Xerna TME biomarker status. Source data are provided as a Source data file.

Back to article page